Insilico, Tenacia expand AI CNS partnership in $94.75M deal

CURRENT FULL VERSION: Insilico Medicine is widening its neuroscience push with Tenacia Biotechnology, expanding a central nervous system drug discovery collaboration that now carries up to $94.75 million in additional potential value. The March 26, 2026, announcement adds a second AI-driven program aimed at difficult neurological diseases, with Insilico eligible for near-term and milestone payments as the work advances. (prnewswire.com)

The move builds on an initial collaboration launched in March 2025. In that first phase, the companies paired Insilico’s generative AI drug discovery platform, Pharma.AI, with Tenacia’s CNS-focused scientific expertise and proprietary data assets. According to the companies, that first program centered on small-molecule inhibitors designed for strong blood-brain barrier permeability, and progress there helped justify a broader deal. (prnewswire.com)

Under the expanded agreement, the companies said they’ll jointly develop an additional candidate with defined properties for challenging neurological diseases and advance it to the preclinical candidate stage. Insilico framed the structure as an effort to generate molecules with distinct profiles against the same target, with the goal of offering a broader and more precise set of therapeutic options while reducing late-stage development risk. That emphasis on tuning molecular properties, not just identifying a target, is notable in CNS drug discovery, where brain exposure, tolerability, and translational performance often derail programs. (prnewswire.com)

The deal also fits a broader pattern for both companies. Tenacia, founded in 2022, has been building a regional neuroscience business through licensing and development deals, including a 2022 collaboration with Marinus around ganaxolone in Greater China and a March 2026 deal with Rapport Therapeutics for RAP-219 in focal onset seizures, bipolar mania, and other indications. In both cases, counterparties pointed to Tenacia’s CNS development and commercialization capabilities in China and the broader Greater China market. (ir.marinuspharma.com)

For Insilico, the Tenacia expansion adds to a steady drumbeat of partnership activity meant to validate its AI platform in real-world dealmaking. Beyond smaller discovery alliances, the company has also pointed to a much larger multi-program collaboration with Eli Lilly spanning multiple therapeutic areas. In that deal, Lilly received exclusive global rights to develop, manufacture, and commercialize Insilico’s preclinical oral candidates for selected indications, while the companies also agreed to work on multiple Lilly-selected targets using Pharma.AI. Insilico said that agreement included $115 million upfront and total potential value of up to $2.75 billion, plus tiered royalties on future sales. That scale matters because it suggests large pharma is willing to use the platform not only for exploratory research but also for assets tied to global rights and downstream commercial economics. (pharmashots.com)

Insilico has also argued that its platform can compress early discovery timelines, saying it moved 20 programs to preclinical candidate nomination from 2021 through 2024 in roughly 12 to 18 months each. That claim comes from the company, so it should be read as a performance benchmark rather than an independent industry consensus, but it helps explain why partners continue to sign on. The Tenacia expansion is smaller and more focused than the Lilly arrangement, but it fits the same broader story: AI collaborations are increasingly being structured around specific assets, targets, and rights rather than generic access to a software tool. (biospace.com)

Why it matters: For veterinary professionals, the direct impact is limited today because this is a human CNS discovery deal, not an animal health program. Still, the underlying trend matters. Neurology, epilepsy, pain, and behavior remain areas of high unmet need in companion animals, and CNS drug development is especially difficult because compounds must balance efficacy, safety, and central penetration. If AI-driven discovery platforms can more reliably design molecules with those properties earlier in development, that could eventually lower barriers for translational work relevant to veterinary medicine, whether through dedicated animal health pipelines or repurposed platform capabilities. The separate Lilly collaboration adds another useful signal: major drugmakers appear willing to place large bets on AI-enabled discovery models when they can secure defined candidates, exclusive rights, and commercial upside. (prnewswire.com)

There’s also a business signal here. The Tenacia expansion suggests that partners are willing to move from exploratory AI collaborations to follow-on programs when early work appears productive. For veterinary industry watchers, that’s useful because it shows where capital is flowing: toward platforms that can pair computational design with disease-specific expertise and region-specific development infrastructure. CNS has historically been one of the hardest proving grounds in drug discovery, so repeat business in this area may carry more weight than another generic AI partnership headline. This is an inference based on the structure and sequencing of the companies’ announced deals. (prnewswire.com)

What to watch: The next milestones are likely to be preclinical candidate nomination, any disclosure of the biological target or first indication, and signs that the collaboration expands beyond discovery into development or territorial rights. If the companies publish data on blood-brain barrier performance or translational models, that will be the clearest evidence of whether this AI-enabled CNS strategy is producing more than deal momentum. The Lilly precedent also makes it worth watching whether future Insilico partnerships include clearer licensing structures, exclusive rights, or royalty-bearing economics once programs mature. (prnewswire.com)